GNFT
Genfit S.A.
Biotechnology
Market Cap$448M
5Y Perf.+71.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
GNFT vs HALO vs ALNY vs ARWR
Revenue, margins, valuation, and 5-year total return — side by side.
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.68B
5Y Perf.+177.3%
ALNY
Alnylam Pharmaceuticals, Inc.
Biotechnology
Market Cap$39.48B
5Y Perf.+194.0%
ARWR
Arrowhead Pharmaceuticals, Inc.
Biotechnology
Market Cap$10.92B
5Y Perf.+105.9%
GNFT vs HALO vs ALNY vs ARWR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GNFT | HALO | ALNY | ARWR |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $448M | $7.68B | $39.48B | $10.92B |
| Revenue (TTM) | $117M | $1.40B | $4.29B | $622M |
| Net Income (TTM) | $-16M | $317M | $577M | $-301M |
| Gross Margin | 104.9% | 81.9% | 80.9% | 85.1% |
| Operating Margin | 0.4% | 58.4% | 17.5% | -35.7% |
| Forward P/E | 256.9x | 8.1x | 44.2x | — |
| Total Debt | $62M | $0.00 | $1.28B | $366M |
| Cash & Equiv. | $82M | $134M | $1.66B | $227M |
GNFT vs HALO vs ALNY vs ARWR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GNFT
HALO
ALNY
ARWR
| Stock | May 20 | Mar 26 | Return |
|---|---|---|---|
| Genfit S.A. (GNFT) | 100 | 171.5 | +71.5% |
| Halozyme Therapeuti… (HALO) | 100 | 277.3 | +177.3% |
| Alnylam Pharmaceuti… (ALNY) | 100 | 294.0 | +194.0% |
| Arrowhead Pharmaceu… (ARWR) | 100 | 205.9 | +105.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GNFT vs HALO vs ALNY vs ARWR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HALO leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Arrowhead Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
GNFT
Genfit S.A.
The Growth Angle
GNFT plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
HALO
Halozyme Therapeutics, Inc.
The Income Pick
HALO carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.56
- Lower volatility, beta 0.56, current ratio 4.66x
- Beta 0.56, current ratio 4.66x
- Better valuation composite
Best for: income & stability and sleep-well-at-night
ALNY
Alnylam Pharmaceuticals, Inc.
The Long-Run Compounder
ALNY is the clearest fit if your priority is long-term compounding.
- 411.9% 10Y total return vs ARWR's 12.5%
Best for: long-term compounding
ARWR
Arrowhead Pharmaceuticals, Inc.
The Growth Play
ARWR is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 232.6%, EPS growth 99.8%, 3Y rev CAGR 50.5%
- 232.6% revenue growth vs HALO's 37.6%
- +496.9% vs HALO's -7.1%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARWR | 232.6% revenue growth vs HALO's 37.6% |
| Value | HALO | Better valuation composite |
| Quality / Margins | HALO | 22.7% margin vs ARWR's -48.4% |
| Stability / Safety | HALO | Beta 0.56 vs ARWR's 1.81 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | ARWR | +496.9% vs HALO's -7.1% |
| Efficiency (ROA) | HALO | 12.5% ROA vs ARWR's -18.1%, ROIC 73.4% vs 9.3% |
GNFT vs HALO vs ALNY vs ARWR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
Segment breakdown not available.
GNFT vs HALO vs ALNY vs ARWR — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHALOLAGGINGARWR
Who Leads Where
HALO leads in 3 of 6 categories
GNFT leads 0 • ALNY leads 0 • ARWR leads 0 • 2 tied
Explore the data ↓ARWRArrowhead Pharmaceuti…
0leads
ALNYAlnylam Pharmaceutica…
0leads
GNFTGenfit S.A.
0leads
HALOHalozyme Therapeutics…
3leads
6 Total Categories
CATEGORYLEADERvs GNFTvs ALNYMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HALO3/6
Valuation MetricsMultiples, price ratios, and targets
HALO4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HALO6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HALO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALNY is the larger business by revenue, generating $4.3B annually — 36.7x GNFT's $117M. HALO is the more profitable business, keeping 22.7% of every revenue dollar as net income compared to ARWR's -48.4%. On growth, ALNY holds the edge at +96.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | GNFTGenfit S.A. | HALOHalozyme Therapeu… | ALNYAlnylam Pharmaceu… | ARWRArrowhead Pharmac… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $117M | $1.4B | $4.3B | $622M |
| EBITDAEarnings before interest/tax | $4M | $945M | $677M | -$203M |
| Net IncomeAfter-tax profit | -$16M | $317M | $577M | -$301M |
| Free Cash FlowCash after capex | -$47M | $645M | $641M | -$51M |
| Gross MarginGross profit ÷ Revenue | +104.9% | +81.9% | +80.9% | +85.1% |
| Operating MarginEBIT ÷ Revenue | +0.4% | +58.4% | +17.5% | -35.7% |
| Net MarginNet income ÷ Revenue | -14.1% | +22.7% | +13.5% | -48.4% |
| FCF MarginFCF ÷ Revenue | -40.4% | +46.2% | +15.0% | -8.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -41.8% | +51.6% | +96.4% | -86.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -140.0% | -2.1% | +4.4% | -133.8% |
HALO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
HALO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 25.5x trailing earnings, HALO trades at a 90% valuation discount to GNFT's 256.9x P/E. On an enterprise value basis, HALO's 8.3x EV/EBITDA is more attractive than ARWR's 90.4x.
| Metric | GNFTGenfit S.A. | HALOHalozyme Therapeu… | ALNYAlnylam Pharmaceu… | ARWRArrowhead Pharmac… |
|---|---|---|---|---|
| Market CapShares × price | $448M | $7.7B | $39.5B | $10.9B |
| Enterprise ValueMkt cap + debt − cash | $425M | $7.5B | $39.1B | $11.1B |
| Trailing P/EPrice ÷ TTM EPS | 256.88x | 25.46x | 127.00x | -6389.34x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 8.09x | 44.18x | — |
| PEG RatioP/E ÷ EPS growth rate | — | 1.11x | — | — |
| EV / EBITDAEnterprise value multiple | 73.07x | 8.34x | 70.17x | 90.41x |
| Price / SalesMarket cap ÷ Revenue | 5.75x | 5.50x | 10.63x | 13.16x |
| Price / BookPrice ÷ Book value/share | 5.59x | 165.47x | 50.50x | 20.71x |
| Price / FCFMarket cap ÷ FCF | 27.10x | 11.91x | 84.84x | 69.58x |
HALO leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
HALO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
HALO delivers a 6.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-55 for ARWR. ARWR carries lower financial leverage with a 0.73x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALNY's 1.62x. On the Piotroski fundamental quality scale (0–9), GNFT scores 6/9 vs HALO's 5/9, reflecting solid financial health.
| Metric | GNFTGenfit S.A. | HALOHalozyme Therapeu… | ALNYAlnylam Pharmaceu… | ARWRArrowhead Pharmac… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -23.0% | +6.5% | +98.3% | -55.5% |
| ROA (TTM)Return on assets | -9.0% | +12.5% | +11.8% | -18.1% |
| ROICReturn on invested capital | +4.5% | +73.4% | +33.4% | +9.3% |
| ROCEReturn on capital employed | +3.1% | +38.2% | +15.3% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.90x | — | 1.62x | 0.73x |
| Net DebtTotal debt minus cash | -$20M | -$134M | -$379M | $140M |
| Cash & Equiv.Liquid assets | $82M | $134M | $1.7B | $227M |
| Total DebtShort + long-term debt | $62M | $0 | $1.3B | $366M |
| Interest CoverageEBIT ÷ Interest expense | -0.67x | 46.08x | 2.02x | -1.03x |
HALO leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — HALO and ARWR each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALNY five years ago would be worth $22,537 today (with dividends reinvested), compared to $11,743 for ARWR. Over the past 12 months, ARWR leads with a +496.9% total return vs HALO's -7.1%. The 3-year compound annual growth rate (CAGR) favors HALO at 29.1% vs ALNY's 12.1% — a key indicator of consistent wealth creation.
| Metric | GNFTGenfit S.A. | HALOHalozyme Therapeu… | ALNYAlnylam Pharmaceu… | ARWRArrowhead Pharmac… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +48.5% | -7.3% | -26.1% | +15.0% |
| 1-Year ReturnPast 12 months | +110.6% | -7.1% | +7.0% | +496.9% |
| 3-Year ReturnCumulative with dividends | +109.6% | +115.3% | +40.9% | +92.7% |
| 5-Year ReturnCumulative with dividends | +111.6% | +37.0% | +125.4% | +17.4% |
| 10-Year ReturnCumulative with dividends | -59.6% | +570.7% | +411.9% | +1253.3% |
| CAGR (3Y)Annualised 3-year return | +28.0% | +29.1% | +12.1% | +24.4% |
Evenly matched — HALO and ARWR each lead in 2 of 6 comparable metrics.
Risk & Volatility
Evenly matched — HALO and ARWR each lead in 1 of 2 comparable metrics.
Risk & Volatility
HALO is the less volatile stock with a 0.56 beta — it tends to amplify market swings less than ARWR's 1.81 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARWR currently trades 98.1% from its 52-week high vs ALNY's 59.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GNFTGenfit S.A. | HALOHalozyme Therapeu… | ALNYAlnylam Pharmaceu… | ARWRArrowhead Pharmac… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 0.56x | 0.71x | 1.81x |
| 52-Week HighHighest price in past year | $10.20 | $82.22 | $495.55 | $79.48 |
| 52-Week LowLowest price in past year | $3.00 | $47.50 | $245.96 | $12.44 |
| % of 52W HighCurrent price vs 52-week peak | +87.7% | +79.3% | +59.7% | +98.1% |
| RSI (14)Momentum oscillator 0–100 | 71.8 | 52.4 | 43.8 | 69.7 |
| Avg Volume (50D)Average daily shares traded | 4K | 1.4M | 1.1M | 1.9M |
Evenly matched — HALO and ARWR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: GNFT as "Buy", HALO as "Buy", ALNY as "Buy", ARWR as "Buy". Consensus price targets imply 50.6% upside for ALNY (target: $446) vs 4.2% for ARWR (target: $81).
| Metric | GNFTGenfit S.A. | HALOHalozyme Therapeu… | ALNYAlnylam Pharmaceu… | ARWRArrowhead Pharmac… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $13.00 | $78.33 | $445.67 | $81.22 |
| # AnalystsCovering analysts | 7 | 27 | 52 | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.5% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
HALO leads in 3 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 2 categories are tied.
Best OverallHalozyme Therapeutics, Inc. (HALO)Leads 3 of 6 categories
Loading custom metrics...
GNFT vs HALO vs ALNY vs ARWR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is GNFT or HALO or ALNY or ARWR a better buy right now?
For growth investors, Arrowhead Pharmaceuticals, Inc.
(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus 37. 6% for Halozyme Therapeutics, Inc. (HALO). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 5x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate Genfit S. A. (GNFT) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GNFT or HALO or ALNY or ARWR?
On trailing P/E, Halozyme Therapeutics, Inc.
(HALO) is the cheapest at 25. 5x versus Genfit S. A. at 256. 9x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 1x.
03Which is the better long-term investment — GNFT or HALO or ALNY or ARWR?
Over the past 5 years, Alnylam Pharmaceuticals, Inc.
(ALNY) delivered a total return of +125. 4%, compared to +17. 4% for Arrowhead Pharmaceuticals, Inc. (ARWR). Over 10 years, the gap is even starker: ARWR returned +1253% versus GNFT's -59. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GNFT or HALO or ALNY or ARWR?
By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.
(HALO) is the lower-risk stock at 0. 56β versus Arrowhead Pharmaceuticals, Inc. 's 1. 81β — meaning ARWR is approximately 225% more volatile than HALO relative to the S&P 500. On balance sheet safety, Arrowhead Pharmaceuticals, Inc. (ARWR) carries a lower debt/equity ratio of 73% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — GNFT or HALO or ALNY or ARWR?
By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.
(ARWR) is pulling ahead at 232. 6% versus 37. 6% for Halozyme Therapeutics, Inc. (HALO). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GNFT or HALO or ALNY or ARWR?
Halozyme Therapeutics, Inc.
(HALO) is the more profitable company, earning 22. 7% net margin versus -0. 2% for Arrowhead Pharmaceuticals, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 4. 9% for GNFT. At the gross margin level — before operating expenses — GNFT leads at 99. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GNFT or HALO or ALNY or ARWR more undervalued right now?
On forward earnings alone, Halozyme Therapeutics, Inc.
(HALO) trades at 8. 1x forward P/E versus 44. 2x for Alnylam Pharmaceuticals, Inc. — 36. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALNY: 50. 6% to $445. 67.
08Which pays a better dividend — GNFT or HALO or ALNY or ARWR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is GNFT or HALO or ALNY or ARWR better for a retirement portfolio?
For long-horizon retirement investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Both have compounded well over 10 years (HALO: +570. 7%, GNFT: -59. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GNFT and HALO and ALNY and ARWR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(GNFT: -41.8% · HALO: 51.6%)P/E Ratio<
x
(GNFT: 256.9x · HALO: 25.5x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.